Inicio>>Signaling Pathways>> Antibody-drug Conjugate/ADC Related>> ADC Linker>>Fmoc-NH-PEG8-CH2COOH

Fmoc-NH-PEG8-CH2COOH

Catalog No.GC64814

Fmoc-NH-PEG8-CH2COOH es un enlazador de ADC escindible que se utiliza en la sÍntesis de conjugados de anticuerpo y fÁrmaco (ADC). Fmoc-NH-PEG8-CH2COOH también es un enlazador PROTAC basado en PEG que se puede usar en la sÍntesis de PROTAC.

Products are for research use only. Not for human use. We do not sell to patients.

Fmoc-NH-PEG8-CH2COOH Chemical Structure

Cas No.: 868594-52-9

Tamaño Precio Disponibilidad Cantidad
25 mg
54,00 $
Disponible
50 mg
81,00 $
Disponible
100 mg
135,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Fmoc-NH-PEG8-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG8-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

[1]. Michael A, et al. Synthesis of Bifunctional Integrin‐Binding Peptides Containing PEG Spacers of Defined Length for Non‐Viral Gene Delivery. Volume2008, Issue17.

Reseñas

Review for Fmoc-NH-PEG8-CH2COOH

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Fmoc-NH-PEG8-CH2COOH

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.